Multiple people across the globe who stepped forward are speaking about what they say is the debilitating aftermath they now ...
The company reported $200 million in net losses for the third quarter, but an aggressive and highly successful cost-cutting ...
WARNING: GRAPHIC CONTENT A grieving husband has claimed his wife died from complications of the Johnson & Johnson COVID-19 ...
Moderna (MRNA), with its widely used COVID-19 vaccine, rose to prominence during the global pandemic. The stock soared an eye-catching 838.4% between 2020 and 2022. But the company is now stepping ...
Johnson & Johnson said on Thursday it has asked U.S. health regulators to authorize its single-dose COVID-19 vaccine for ...
RSV is a leading cause of infant hospitalizations in Canada, with older people and those who are immunocompromised also at greater risk ...
MedPage Today on MSN
Intranasal Flu Vaccine Shows Promise in Early Trial
For intramuscular vaccines, the standard hemagglutination inhibition (HAI) titer used to infer immune protection is at least ...
Jefferies London Healthcare Conference 2025 November 18, 2025 12:00 PM ESTCompany ParticipantsMatthew Gline - CEO ...
Biotech Vertex Pharmaceuticals stock tumbled on news of disappointing drug data. CEO Reshma Kewalramani paid nearly $4 million to buy shares. Novo Nordisk Stock Could Benefit From Eli Lilly’s ...
The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...
Moderna is backing the American Lung Association’s (ALA’s) call for people with lung diseases to get vaccinated for the upcoming respiratory virus season. The biotech, which sells vaccines against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback